Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.65), in-line with the analyst estimate of ($0.65). Revenue for the quarter came in at $0 , versus $30 thousand reported last year.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c